Fourteenth of the "ASCO Direct™ China" webinar:Dialogue Meeting on the ASCO Guideline for Treatment of Locally Advanced Esophageal Carcinoma

About this Event

Webinar Date:

  • China Time: Saturday October 31th, 9:00AM
  • US EST Time: Friday, October 30th, 9:00PM
  • US PST Time: Friday, October 30th, 6:00PM

Conference Language: English

Venue: Live Zoom Webinar

Webinar Agenda

Chairs:

  • Dr. Manish A Shah, New York Hospital, Weill Cornell Medicine
  • Dr. Yongtao Han, Sichuan Cancer Hospital

Presentations:

Treatment of locally advanced esophageal carcinoma: 2020 ASCO Guideline

  • Dr. Manish A Shah, New York Hospital, Weill Cornell Medicine

Clinical progress of immunotherapy in neoadjuvant and adjuvant therapy for Locally advanced esophageal cancer

  • Dr. Jun Wang, The Fourth Hospital of Hebei Medical University

Panel Discussion

Chairs

  • Dr. Manish A Shah, New York Hospital, Weill Cornell Medicine
  • Dr. Yongtao Han, Sichuan Cancer Hospital

Topics

Consideration factor of neoadjuvant and adjuvant therapy for locally advanced esophageal squamous cell carcinoma and adenocarcinoma in clinical practice.

Role of immunotherapy in neoadjuvant and adjuvant therapy for Locally advanced esophageal cancer.

Guests

  • Dr. Bas Wijnhoven, Erasmus University Medical Center
  • Dr. Karyn Goodman, Mount Sinai Icanhn School of Medicine
  • Dr. Jun Wang, The Fourth Hospital of Hebei Medical University
  • Dr. Nan Bi, Cancer Hospital Chinese Academy of Medical Sciences
  • Dr. Qingsong Pang, Tianjin Medical University Cancer Institute and Hospital
  • Dr. Shuanghu Yuan, Shandong Cancer Hospital & Institute
  • Dr. Xiaozheng Kang, Peking University Cancer Hospital

Speakers and Panelists Bio

          

Dr. Manish A Shah, New York Hospital, Weill Cornell Medicine

Manish A. Shah, the Bartlett Family Professor of Gastrointestinal Oncology, is internationally recognized as a prominent clinical and translational investigator focusing on drug development and advancing the care of gastrointestinal malignancies. He leads an active program in drug development in gastric and esophageal cancers. He received a BES in Biomedical Engineering from Johns Hopkins University; MD from the Harvard/MIT Health Sciences and Training program; and completed his training in Oncology at Memorial Sloan Kettering / Weill Cornell Medicine, where he was chief fellow. Presently, Dr. Shah is Chief, Solid Tumor Oncology Service; Director, Gastrointestinal Oncology Program at Weill Cornell Medicine and Co-Director, Center for Advanced Digestive Care, New York Presbyterian Hospital.

          

Dr. Yongtao Han, Sichuan Cancer Hospital

  • Director of Esophageal Surgery Center, Sichuan Cancer Hospital
  • Professor, Chief Physician, Master Supervisor
  • Chairman of Esophageal cancer Expert Committee, Chinese Society of Clinical Oncology
  • Vice Chairman of Esophageal cancer Professional Committee, Chinese Anti Cancer Association
  • Member of Thoracic and cardiovascular surgery Professional Committee, Chinese Medical Association
  • Fellow of the Royal College of Surgeons of England
  • Member of the International Society for Diseases of the Esophagus and Standing Member of the Chinese Society for Diseases of the Esophagus
  • Head of National Esophageal Cancer Clinical Research Sub-center
  • Person in charge of National Standardized Diagnosis and Treatment for Esophageal Cancer Training base
  • Sichuan Group Leader, National Supporting Projects of "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan"
  • Member of Academic Committee, West China Society of Therapeutic and Radiation Oncology
  • Standing Member of the Thoracic Neoplasm Professional Committee, West China Society of Therapeutic and Radiation Oncology
  • Academic technology leader of Sichuan Provincial Health Department
  • Chairman of Esophageal cancer Professional Committee, Sichuan Anti Cancer Association
  • Standing Member of Thoracic and cardiovascular surgery Professional Committee, Sichuan Medical Association
  • Vice Leader of Esophageal Cancer Group, Sichuan Medical Association
  • Vice Leader of Esophagogastric Junction Oncology Group, Sichuan Medical Association
  • Standing Member of Minimally Invasive Surgery Professional Committee, Shaanxi Anti Cancer Association
  • Associate Editor of esophageal cancer
  • Editorial Board Member of Chinese Clinical Practice Guidelines for the Diagnosis and Treatment of Esophageal Cancer
  • Editorial Board Member of Concise Handbook of Minimally Invasive Surgery for esophageal carcinoma
  • Editorial Board Member of Cancer

          

Dr. Jun Wang, The Fourth Hospital of Hebei Medical University

  • First ward director of Radiotherapy, The Fourth Hospital of Hebei Medical University
  • Alternate Chairman of Radiation Oncology, Hebei Medical Association
  • Member of Lung Cancer Professional Committee, Chinese Anti-Cancer Association
  • Vice Chairman of Youth Committee, Radiation Oncology Professional Committee, Chinese Anti-Cancer Association
  • Youth Member of Esophageal cancer Professional Committee, Chinese Anti-Cancer Association
  • Standing Member of Radiotherapy Branch, Oncology Professional Committee, Gerontological Society of China
  • Vice Chairman of Professional Committee of Radiobiology and Multimodality Diagnosis and Treatment, Chinese Research Hospital Association
  • Vice Chairman of Executive Committee, The World Chinese Radiation Therapy Oncology Group
  • The research direction is basis and clinic of the thoracic neoplasm radiotherapy, and radiological heart injury
  • Won 2 second prizes of Hebei science and technology progress
  • Won 3 first prizes of Hebei medical science and technology
  • Two invention patents

Dr. Bas Wijnhoven, Erasmus University Medical Center

Bas Wijnhoven (born in 1970) went to medical school in Utrecht the Netherlands. After obtaining his MD in 1997 he started a PhD program on molecular and clinical aspects of oesophageal cancer at the Erasmus MC in Rotterdam. In 2001 he received his PhD with honor. In the year 2006 he was registered as general surgeon. From 2006 till 2008 he worked as a researcher and surgeon at the Department of Surgery, Flinders Medical Center, Adelaide, Australia. Within these two years he enjoyed a fellowship in upper gastrointestinal and hepatobiliairy surgery. Since 2008 he is appointed as staff surgeon at the Erasmus MC Rotterdam and is program leader on oesophageal and gastric diseases. His clinical interests are benign and malignant diseases of the upper gastrointestinal tract. Research is focused on studies on clinical outcome after surgery for gastric and oesophageal cancer and the molecular biology of Barrett’s oesophagus and adenocarcinoma. In close collaboration with other departments within the Erasmus MC, preclinical and clinical studies on neoadjuvant treatment for oesophageal and gastric cardia cancer are another area of great interest. Dr. Wijnhoven is interested in medical publishing and since 2014 he is full-editor for BJS (British Journal of Surgery). He has authored and co-authored over 250 articles in national and international peer-reviewed journals.

          

Dr. Karyn Goodman, Mount Sinai Icanhn School of Medicine

Karyn Aalami Goodman, MD, MS, is Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute. Dr. Goodman is responsible for developing the infrastructure and resources to support cancer clinical trials across the Mount Sinai Health System. Dr. Goodman earned her MD from Stanford University and MS from Harvard School of Public Health. She completed an internship in internal medicine at Stanford and residency training in radiation oncology at Memorial Sloan Kettering Cancer Center.

Before joining Mount Sinai in September 2019, Dr. Goodman was Associate Director of Clinical Research at the University of Colorado Cancer Center, where she had worked since 2015. Previously, Dr. Goodman was the head of Gastrointestinal Radiation Oncology at Memorial Sloan Kettering Cancer Center from 2007 to 2015. She began her academic medicine career as an Assistant Professor, Radiation Oncology, at Stanford University in 2004.

An internationally recognized expert on gastrointestinal cancers, Dr. Goodman has served with several organizations, including the ASCO, ASTRO and the ACR, to establish national treatment guidelines and best practices. She serves as Co-chair for the NCI Gastrointestinal Steering Committee. Dr. Goodman’s research focuses on improving outcomes and reducing toxicity in patients with gastrointestinal malignancies. With extensive experience as principal investigator on clinical trials, she is involved in development of therapeutic protocols combining radiation, chemotherapy, targeted agents, and immunotherapy. She has published over 180 peer-reviewed scientific articles, review articles, and chapters.

          

Dr. Nan Bi, Cancer Hospital Chinese Academy of Medical Sciences

  • Professor Radiation Oncologist of National Cancer Center/Cancer Hospital, CAMS&PUMC
  • Vice Director of Department of Radiation Oncology National Cancer Center/Cancer Hospital, CAMS&PUMC
  • Director of Thoracic Tumor Program
  • Fellow of Chinese Society of Clinical Oncology (CSCO)
  • Yong Fellow of Chinese Society of Radiation Oncology(CSTRO)
  • Yong Fellow of Chinese Society of Lung Cancer
  • Yong Fellow of Chinese Society of Radiation Oncology
  • Member of Innovation team of the Ministry of Education
  • Received numerous awards such as ‘Developing Nation Travel Award’ of IASLC and Young Investigator Award of SANTRO.
  • 50+ SCI publications (IF > 200)
  • Reviewer of Int J Radiat Oncol Biol Phys 、Eur J Cancer、Oncologist, et al.

          

Dr. Qingsong Pang, Tianjin Medical University Cancer Institute and Hospital

  • Chief Physician of Thoracic Treatment Group, Radiotherapy Department, Tianjin Medical University Cancer Institute & Hospital
  • Doctor of Oncology
  • Committee Member of Radiobiology Group, Radiation Oncology Branch, Chinese Medical Association
  • Secretary General of Youth Committee of Radiation Oncology Branch of Chinese Anti-Cancer Association
  • Committee Member of Radiotherapy Group, Cancer Rehabilitation and Palliative Therapy Society of China Anti-Cancer Association
  • Standing Committee Member and Secretary General of Radiation Oncology Branch, Tianjin Medical Association
  • Committee Member of Mediastinal Society of Chinese Society of Clinical Oncology (CSCO)
  • Committee Member of Cancer Radiotherapy Society of Chinese Society of Clinical Oncology (CSCO)
  • Deputy Leader of Beijing-Tianjin-Hebei Esophageal Cancer Collaborative Group
  • Communication Editorial Board Member of Chinese Journal of Radiological Medicine and Protection; Reviewers of Chinese Journal of Radiation Oncology, Chinese Journal of Clinical Oncology, Chinese Journal of Cancer, International Journal of Radiation Medicine and Nuclear Medicine

          

Dr. Shuanghu Yuan, Shandong Cancer Hospital & Institute

  • Professor and Chair of Thoracic Radiaiton Oncology Department at Shandong Cancer Hospital & Institute,Shandong First Medical University
  • State Council Expert for Special Allowance
  • Chairman of the Executive Committee, CRTOG
  • Standing Committee of Lung Cancer at CACA and CSCO(Chinese Society of Clinical Oncology)
  • Vice Chairman, Youth Committee of CSTRO
  • General research interests: Clinical and translational research in brain and thoracic tumor

          

Dr. Xiaozheng Kang, Peking University Cancer Hospital

  • Young Committee Member of Chinese Society of Clinical Oncology (CSCO)
  • Young Committee Member of Esophageal Cancer Branch, Chinese Anti-Cancer Association (CACA)
  • Young Committee Member of Thoracic Surgery Branch, Beijing Medical Association (BATS)

Treatment of Locally Advanced Esophageal Carcinoma

ASCO Abstract # 4572

Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study

ASCO Abstract # 4556

Intestinal and tumor microbiome analysis combined with metabolomics of the anti-PD-L1 phase II PERFECT trial for resectable esophageal adenocarcinoma


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device.


Organizers:

        

                                 

Partners:

                                           

                                          

Exclusive Live Streaming Platform:

                                     

Welcome

Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.